PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma

Cancer Research

Volumn 72, Issue 7, 2012, Pages 1608-1613

  Brenner, J Chad ^a,b,c   Feng, Felix Y ^a,c   Han, Sumin ^c   Patel, Sonam ^a,b   Goyal, Siddharth V ^a,b   Bou Maroun, Laura M ^a,b   Liu, Meilan ^c   Lonigro, Robert ^a,b   Prensner, John R ^a,b   Tomlins, Scott A ^a,b   Chinnaiyan, Arul M ^a,b,c  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; OLAPARIB; TEMOZOLOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DNA DAMAGE; DRUG POTENTIATION; DRUG TARGETING; ENZYME INHIBITION; EWING SARCOMA; EWING SARCOMA BREAKPOINT REGION 1 GENE; FUSION GENE; GENE FUSION; GENE INTERACTION; METASTASIS; METASTASIS INHIBITION; MONOTHERAPY; MOUSE; NONHUMAN; POSITIVE FEEDBACK; PRIMARY TUMOR; PRIORITY JOURNAL; TRANSCRIPTION FACTOR FLI1 GENE; TRANSCRIPTION REGULATION; TUMOR XENOGRAFT;

ANIMALS; BONE NEOPLASMS; CELL LINE, TUMOR; HUMANS; MICE; ONCOGENE PROTEINS, FUSION; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEIN C-FLI-1; RNA-BINDING PROTEIN EWS; SARCOMA, EWING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84859391984     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-3648     Document Type: Article

References (19)

1. Burchill SA. Ewing's sarcoma: diagnostic, prognostic, and therapeutic implications of molecular abnormalities. J Clin Pathol 2003;56:96-102.
2. de Alava E, Kawai A, Healey JH, Fligman I, Meyers PA, Huvos AG, et al. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol 1998;16:1248-55.
3. Brenner JC, Chinnaiyan AM. Translocations in epithelial cancers. Biochim Biophys Acta 2009;1796:201-15.
4. Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007;448:595-9. (Pubitemid 47206938)
5. Pinkerton CR, Bataillard A, Guillo S, Oberlin O, Fervers B, Philip T. Treatment strategies for metastatic Ewing's sarcoma. Eur J Cancer 2001;37:1338-44. (Pubitemid 32588743)
6. Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 2011;19: 664-78.
7. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-8. (Pubitemid 41528150)
8. Welford SM, Hebert SP, Deneen B, Arvand A, Denny CT. DNA binding domain-independent pathways are involved in EWS/FLI1-mediated oncogenesis. J Biol Chem 2001;276:41977-84.
9. +-dependent modulation of chromatin structure and transcription by nucleosome binding properties of PARP-1. Cell 2004;119:803-14.
10. Krishnakumar R, Gamble MJ, Frizzell KM, Berrocal JG, Kininis M, Kraus WL. Reciprocal binding of PARP-1 and histone H1 at promoters specifies transcriptional outcomes. Science 2008;319:819-21. (Pubitemid 351225873)
11. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. Nat Rev Cancer 2010;10:293-301.
12. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-34.
13. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature 2005;434:913-7. (Pubitemid 40559005)
14. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21. (Pubitemid 40559006)
15. Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007;13:2728-37. (Pubitemid 46795129)
16. Wagner LM, McAllister N, Goldsby RE, Rausen AR, McNall-Knapp RY, McCarville MB, et al. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer 2007;48:132-9. (Pubitemid 44958268)
17. Siligan C, Ban J, Bachmaier R, Spahn L, Kreppel M, Schaefer KL., et al. EWS-FLI1 target genes recovered from Ewing's sarcoma chromatin. Oncogene 2005;24:2512-24. (Pubitemid 40593042)
18. Soldatenkov VA, Albor A, Patel BK, Dreszer R, Dritschilo A, Notario V. Regulation of the human poly(ADP-ribose) polymerase promoter by the ETS transcription factor. Oncogene 1999;18:3954-62. (Pubitemid 29361333)
19. Newman RE, Soldatenkov VA, Dritschilo A, Notario V. Poly(ADP-ribose) polymerase turnover alterations do not contribute to PARP overexpression in Ewing's sarcoma cells. Oncol Rep 2002;9: 529-32.